Live feed08:20:52·7mANALYSTRatingvia QuantisnowH.C. Wainwright resumed coverage on Larimar Therapeutics with a new price targetByQuantisnow·Wall Street's wire, on your screen.LRMR· Larimar Therapeutics Inc.Health CareOriginal source